296 related articles for article (PubMed ID: 1811418)
1. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
Kurnick JT; Kradin RL
Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
[No Abstract] [Full Text] [Related]
2. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
3. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
Li D; Zhang X; Song Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
[TBL] [Abstract][Full Text] [Related]
5. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
Melief CJ
Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
[No Abstract] [Full Text] [Related]
6. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived activated cells: culture conditions and characterization.
Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
[No Abstract] [Full Text] [Related]
9. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
Wolf JA; Grimm EA
Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968
[No Abstract] [Full Text] [Related]
10. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
[TBL] [Abstract][Full Text] [Related]
11. The role of interleukin-2 in cancer immunotherapy.
Eberlein TJ; Schoof DD
Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612
[TBL] [Abstract][Full Text] [Related]
12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
13. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
Yannelli JR; Wroblewski JM
Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
[TBL] [Abstract][Full Text] [Related]
14. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
Zanovello P; Rosato A; Bronte V; Cerundolo V; Collavo D
Ann Ist Super Sanita; 1991; 27(1):91-5. PubMed ID: 1958033
[TBL] [Abstract][Full Text] [Related]
17. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
Han B; Jia Y; Zhou M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
[TBL] [Abstract][Full Text] [Related]
18. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
Oldham RK
Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
[No Abstract] [Full Text] [Related]
19. [Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination].
Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Tamai M; Taniguchi K; Aoki Y
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1558-64. PubMed ID: 2172423
[TBL] [Abstract][Full Text] [Related]
20. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]